Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada

Clinical Infectious Diseases

Volumn 40, Issue 11, 2005, Pages 1591-1597

  Pépin, Jacques ^a,b   Alary, Marie Eve ^a   Valiquette, Louis ^a   Raiche, Evelyne ^a   Ruel, Joannie ^a   Fulop, Katalin ^a   Godin, Dominique ^a   Bourassa, Claude ^a  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

METRONIDAZOLE; PROBIOTIC AGENT; VANCOMYCIN;

CANADA; CLOSTRIDIUM DIFFICILE; COLITIS; DIARRHEA; DRUG DOSE REGIMEN; HOSPITALIZATION; HUMAN; KAPLAN MEIER METHOD; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROBABILITY; RECURRENT DISEASE; RELAPSE; REVIEW; RISK FACTOR; SACCHAROMYCES BOULARDII; TREATMENT FAILURE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; INFANT; METRONIDAZOLE; MIDDLE AGED; QUEBEC; RECURRENCE; RISK FACTORS; TREATMENT FAILURE; VANCOMYCIN;

EID: 19344363493     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/430315     Document Type: Review

References (34)

1. Bartlett JG, Chang TW, Gurwith M, et al. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med 1978; 298: 531-4.
2. Teasley DG, Gerding DN, Olson MM, et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficile-associated diarrhea and colitis. Lancet 1983; 2:1043-6.
3. Wilcox MH, Spencer RC. Clostridium difficile infection: responses, relapses and re-infections. J Hosp Infect 1992; 22:85-92.
4. Centers for Disease Control and Prevention. Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Morb Mortal Wkly Rep 1995; 44(RR-12):1-13. Available at: http://www.cdc.gov/mmwr/PDF/rr/rr4412. pdf.
5. Bartlett J. Clostridium difficile: clinical considerations. Rev Infect Dis 1990; 12(Suppl 2):S243-51.
6. Olson MM, Shanholtzer CJ, Lee JT, Gerding DN. Ten years of prospective Clostridium difficile associated disease surveillance and treatment at the Minneapolis VA Medical Center. Infect Control Hosp Epidemiol 1994; 15:371-81.
7. Wenisch C, Parschalk B, Hasenhundl M, Hirschl AM. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 1996; 22:813-8.
8. Gerding DN, Johnson S, Peterson LR, Mulligan ME, Silva J. Clostridium difficile associated diarrhea and colitis. Infect Control Hosp Epidemiol 1995; 16:459-77.
9. Fekety R. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. Am J Gastroenterol 1997; 92:739-50.
10. Johnson SJ, Gerding DN. Clostridium difficile-associated diarrhea. Clin Infect Dis 1998; 26:1027-36.
11. Dudley MN, McLaughlin JC, Carrington G, Frick J, Nightingale CH, Quintiliani R. Oral bacitracin vs. vancomycin therapy for Clostridium difficile-induced diarrhea: a randomized double-blind trial. Arch Intern Med 1986; 146:1101-4.
12. Young GP, Ward PB, Bayley N, et al. Antibiotic-associated colitis due to Clostridium difficile: double-blind comparison of vancomycin and bacitracin. Gastroenterology 1985; 89:1038-45.
13. Eggertson L, Sibbald B. Hospitals battling outbreaks of C. difficile. CMAJ 2004; 171:19-21.
14. Pépin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004; 171:466-72.
15. Bartlett JG. Antibiotic-associated diarrhea. N Engl J Med 2002; 346:334-9.
16. McFarland LV. Epidemiology, risk factors and treatments for antibiotic-associated diarrhea. Dig Dis 1998; 16:292-307.
17. Kelly CP, LaMont JT. Clostridium difficile infection. Annu Rev Med 1998; 49:375-90.
18. Poutanen SM, Simor AF. Clostridiutn difficile-associated diarrhea in adults. CMAJ 2004; 171:51-8.
19. Ministère de la Santé et des Services Sociaux. Nombre d'hospitalisations, durée de séjour et séjour moyen, en soins de courte durée actifs selon le sexe et la phase de vie, 1992-1993 et 2002-2003. Available at: http://www.msss.gouv.qc.ca/statistiques/produc_util. html. Accessed 13 April 2005.
20. Bolton RP, Culshaw MA. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 1986; 27:1169-72.
21. Thielman NM, Wilson KH. Antibiotic-associated colitis. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. 6th ed. Philadelphia: Elsevier Churchill Livingstone, 2005:1249-62.
22. Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000; 342:390-7.
23. Kyne L, Warny M Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhea. Lancet 2001; 357:189-93.
24. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994; 271:1913-8.
25. Surawicz CM, McFarland LV, Greenberg RN, et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 2000; 31:1012-7.
26. Sawyer PR, Brogden RN, Pinder RM, Speight TM, Avery GS. Tinidazole: a review of its antiprotozoal activity and therapeutic efficacy. Drugs 1976; 11:423-40.
27. Noguchi Y, Tanaka T. Aspects of the pharmacology and pharmacokinetics of nitroimidazoles with special reference to tinidazole. Drugs 1978; 15(Suppl 1):10-5.
28. Nord CE. Microbiological properties of tinidazole: spectrum, activity and ecological considerations. J Antimicrob Chemother 1982; 10(Suppl A):35-42.
29. Carmine AA, Brogden RN, Heel RC, Speight TM, Avery GS. Tinidazole in anaerobic infections: a review of its antibacterial activity, pharmacological properties and therapeutic efficacy. Drugs 1982; 24:85-117.
30. Jokipii AM, Jokipii L. Comparative activity of metronidazole and tinidazole against Clostridium difficile and Peptostreptococcus anaerobius. Antimicrob Agents Chemother 1987; 31:183-6.
31. Citron DM, Merriam CV, Tyrrell KL, Warren YA, Fernadez H, Goldstein EJ. In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin and four other antimicrobials against intestinal anaerobic bacteria. Antimicrob Agents Chemother 2003; 47:2334-8.
32. Goldstein EJ, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT. In vitro activities of daptomycin, vancomycin, quinupristin-dalfopristin, linezolid and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates. Antimicrob Agents Chemother 2003; 47:337-41.
33. McVay CS, Rolfe RD. The in vitro and in vivo activities of nitazoxanide against Clostridium difficile. Antimicrob Agents Chemother 2000; 44:2254-8.
34. Eggertson L. C. difficile: by the numbers. CMAJ 2004; 171:1331-2.